ANO17 and Its Interacting Partners TRIO, GPS2, HMMR and DIPA Regulate Adipogenesis in 3T3-L1 Cells

Xiu-Fen Liu, Tapan K. Bera, Charissa Kahue, Thelma Escobar, Zhaoliang Fei, Gregory A. Raciti, Ira Pastan

Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America

Abstract

Partial inactivation of the Ankyrin repeat domain 26 (Ankrd26) gene causes obesity and diabetes in mice and increases spontaneous and induced adipogenesis in mouse embryonic fibroblasts. However, it is not yet known how the Ankrd26 protein carries out its biological functions. We identified by yeast two-hybrid and immunoprecipitation assays the triple functional domain protein (TRIO), the G protein pathway suppressor 2 (GPS2), the delta-interacting protein A (DIPA) and the hyaluronan-mediated motility receptor (HMMR) as ANKRD26 interacting partners. Adipogenesis of 3T3-L1 cells was increased by selective down-regulation of Ankrd26, Trio, Gps2, Hmmr and Dipa. Furthermore, Gps2 and Dipa, which are normally located in the nucleus, were translocated to the cytoplasm, when the C-terminus of ANKRD26 was introduced into these cells. These findings provide biochemical evidence that ANKRD26, TRIO, GPS2 and HMMR are novel and important regulators of adipogenesis and identify new targets for the modulation of adipogenesis.

Introduction

The current epidemic of obesity and diabetes has stimulated research to improve the understanding of these diseases and to identify and characterize new genes involved in their pathogenesis [1–5]. We recently demonstrated that the Ankyrin repeat domain 26 (Ankrd26) gene plays an important role in the development of these pathologies. Mice with partial inactivation of the Ankrd26 gene develop marked hyperphagia, severe obesity and an unusual form of diabetes in which white adipose tissue preserves its sensitivity to insulin [6,7]. Moreover, when young Ankrd26 deficient mice were placed on a pair-feeding diet with normal mice, they maintained normal body weight, showed a better glucose tolerance, and increased insulin sensitivity in the white adipose tissue, indicating a dual role of the Ankrd26 gene in the control of appetite and of adipose tissue insulin sensitivity [7]. In addition, mouse embryonic fibroblasts (MEFs) from these mice have a higher rate of spontaneous and induced adipogenesis compared to normal MEFs and their differentiation to adipocytes is greatly increased when they are exposed to a mixture of adipogenic inducers [8], indicating a prominent role of the Ankrd26 gene in fat cells.

The Ankrd26 protein is highly expressed in the hypothalamus and other regions of the brain, as well as in many tissues and organs, including white adipose tissue. The protein is located in the cytosol close to the inner aspect of the cell membrane in HeLa and 293T cells expressing ANKRD26-EGFP, and it contains both ankyrin repeats and spectrin helices, through which it is potentially able to interact with other proteins [6]. However, it is not yet known what these proteins are and how the Ankrd26 protein carries out its biological functions.

In the present work, we used yeast two-hybrid and immunoprecipitation assays to identify interacting partners for the Ankrd26 protein, and performed knock-down experiments to establish whether any of these interacting proteins were functionally relevant in adipogenesis and whether this process was carried out by their interaction with Ankrd26 protein.

Results

Identification of ANKRD26 protein interaction partners

To identify potential interacting partners of the ANKRD26 protein, we performed yeast two-hybrid screening using 18 baits, encoding overlapping fragments from the full-length ANKRD26 protein sequence (Figure 1). The baits were screened with three different cDNA expression libraries generated from human adult brain, human testis and mouse 11.5-day embryo, tissues known to express ANKRD26 [6]. Thirteen independent interacting proteins were identified by the screening, and 12 of them bound to the coiled-coil domain in the C-terminus, suggesting a prominent role of this domain for Ankrd26 protein-protein interactions (Table 1).

Validation of ANKRD26 protein interaction partners by IP

Among the 13 interacting partners, we selected five to validate their interactions with ANKRD26 in mammalian cells. These are the triple functional domain protein (TRIO), G-protein pathway...
suppressor 2 (Gps2), delta interacting protein A (DIPA; also called coiled-coil domain-containing protein 85B, Ccdc85b), hyaluronan-mediated motility receptor (HMMR), and Ras association (RalGDS/AF-6) domain family (N-terminal) member 7 (Rassf7; also referred to as LOC66985). Because all five partners interact with the C-terminus region of ANKRD26, we generated an expression plasmid containing the last 498 amino acids of human ANKRD26 (1212–1710 fragment) fused to a FLAG epitope tag located at the N-terminus of the protein (Flag-ANKRD26-C). Then a series of IP assays were performed in 293/T cells transiently co-transfected with Flag-ANKRD26-C and with different vectors, each expressing one of the selected proteins. IP analysis confirmed positive interactions for TRIO, GPS2, DIPA, and HMMR (Figure 2). No interaction was observed for Rassf7 (data not shown).

ANKRD26/TRIO interaction by IP
Among the 13 interacting candidates, TRIO was pulled out once during the two-hybrid screening from the mouse embryo cDNA library (Table 1). TRIO is a triple functional domain protein that promotes Ras homolog gene family (Rho) and Ras-related C3 botulinum toxin substrate 1 (Rac1) activation through the exchange of GDP by GTP [9]. Also with the protein tyrosine phosphatase (LAR) it plays a role in coordinating cell-matrix and cytoskeletal rearrangements necessary for cell migration and cell growth [10,11]. To validate the TRIO interaction with

---

**Table 1. Interactors for ANKRD26 identified by yeast two-hybrid screening.**

| cDNA Library       | Identity   | ANKRD26 Interacting Region (aa residues) | Description                                | Frequency | Confirmed |
|--------------------|------------|------------------------------------------|--------------------------------------------|-----------|-----------|
| Human brain        | ANKR17     | 1–199                                    | Ankyrin repeat domain 17                  | 1         | ND        |
| Human testis       | ANKR18B    | 1320–1535                                | Ankyrin repeat domain 18B                 | 3         | ND        |
|                    | C10RF9     | 1320–1535                                | Chromosome 1 open reading frame 9, isoform 1 | 1         | ND        |
|                    | GCC2       | 1344–1638                                | GRIP and coiled-coil domain containing 2, isoform a | 1         | ND        |
|                    | LOC375010  | 1320–1535                                | Hypothetical protein                      | 1         | ND        |
| Mouse 11.5 days    | Ccdc85b    | 1090–1638                                | Coiled-coil domain containing 85B         | 4         | Yes       |
| embryo             | Cxxc1      | 901–1100                                 | CXXC finger 1                             | 1         | ND        |
|                    | Fb1        | 1320–1535                                | Fb1                                       | 1         | ND        |
|                    | Gps2       | 1320–1535                                | G protein pathway suppressor 2            | 2         | Yes       |
|                    | HMMR       | 1320–1638                                | Hyaluron mediated motility receptor       | 2         | Yes       |
|                    | LOC66985   | 1344–1638                                | Rassf7 Ras association (RalGDS/AF-6) domain family 7 | 1         | No        |
|                    | Trio       | 1519–1702                                | Triple functional domain (PTPRF interacting), isoform 5 | 1         | Yes       |
|                    | Sdccag8    | 1090–1267                                | Serologically defined colon               | 1         | ND        |

*Frequency: number of times pulled out during the two-hybrid screening.*
*Confirmed: confirmation of screening results by co-immunoprecipitation.*
*ND: not done.*

doi:10.1371/journal.pone.0038130.t001

---
ANKRD26 in 293T cells, we cloned the TRIO interacting region (aa 773–1059) into a pcDNA3.1 vector with a myc-epitope tag and co-transfected it with pFlag-ANKRD26-C into 293/T cells. Whole cell extracts were immunoprecipitated with anti-Myc antibody followed by immunoblot analysis with both anti-Flag and anti-Myc antibodies. Figure 2A shows that both TRIO-Myc (lane 2) and Flag-ANKRD26-C (lanes 5 and 6) proteins were expressed in 293/T cells, and that the Flag-ANKRD26-C protein was efficiently immunoprecipitated by TRIO-Myc protein (lane 0), validating their interaction in mammalian cells.

**ANKRD26/GPS2 interaction by IP**

GPS2 was pulled out two times from the mouse 11.5-day embryo cDNA library (Table 1). GPS2, encoded by the CCDC85B gene, has a structural homology to hepatitis delta virus (HDV) [15]. GPS2 has been reported as an inhibitory partner of the G-protein-coupled receptors [16]. We co-transfected the Flag-ANKRD26-C expression vector with a Myc epitope tagged DIPA (DIPA-Myc) vector into 293/T cells. As shown in Figure 2B, DIPA-Myc and Flag-ANKRD26-C proteins are well expressed in 293T cells (lanes 2, 5 and 6), and the IP for the DIPA-Myc fragment specifically pulled down Flag-ANKRD26-C protein (lane 8). Similar results were obtained for IP experiment using an EGFP tagged ANKRD26-C construct (data not shown). Both data validate that a DIPA/ANKRD26-C interaction can occur in mammalian cells.

**ANKRD26/HMMR interaction by IP**

During the two-hybrid screening HMMR was pulled out four times from the mouse 11.5-day embryo cDNA library (Table 1). The HMMR gene encodes a protein with a dual action. Within the cell it associates with microtubules and plays a role in the regulation of mitosis [17], while when released into the extracellular space, it can activate intracellular signaling pathways upon association with CD44 and hyaluronan [18]. Its interaction with ANKRD26 was validated by co-transfecting the Flag-ANKRD26-C vector and the Myc-tagged HMMR vector into 293/T cells. As shown in Figure 2D, both HMMR-Myc and Flag-ANKRD26-C proteins are detectable in transfected 293/T cells (lanes 2 and 5) and the anti-Myc antibody efficiently pulled down Flag-ANKRD26-C (lane 8).

**Role of Ankrd26, Trio, Gps2, Hmmr and Dipa in adipogenesis**

Because ablation of the C-terminus of Ankrd26 modulates adipogenesis in MEFs [8], we sought to establish whether Ankrd26 and/or any of its interacting partners have a role in differentiation of 3T3-L1 cells, which are widely used for adipogenesis differentiation studies [19]. The transduction of 3T3-L1 cells with a specific shRNA for Ankrd26 (Ankrd-sh) resulted in a 65% reduction of Ankrd26 mRNA compared to parental 3T3-L1 cells transfected with a non-specific shRNA (Co-sh) (Figure 3A). When differentiation was induced by an adipogenic cocktail for 5 days, Ankrd26 down-regulation caused a 2.5-fold increase in adipogenesis compared to the control cells as shown by the accumulation of triglycerides in the cells (Figure 3B and C), indicating that the down-regulation of Ankrd26, as well as its partial ablation [8], modulates differentiation in fat cells.

We then focused our attention on ANKRD26 partners TRIO, which is a Rho and Rac activator and a LAR interacting partner [9–11], GPS2, and DIPA, which have been reported to control gene expression by inhibition of transcription [14,16,20] and HMMR, which can regulate cell migratory behavior and mitosis [17,18]. In 3T3-L1 cells, Trio shRNA induced a 60% decrease of Trio mRNA levels (Figure 3D), and its down-regulation was paralleled by a 5-fold increase in adipogenesis compared with a control shRNA (Figure 3E and F). Gps2 shRNA produced an 80% decrease of Gps2 mRNA levels (Figure 3G), and this strong down-regulation was accompanied by a 3-fold increase in adipogenesis (Figure 3H and I). HMMR shRNA produced a 74% decrease in adipogenes...
RNA levels (Figure 3f), which was accompanied by a 3-fold increase in adipogenesis (Figure 3K and L). Finally, when Dipa shRNA was transfected in 3T3-L1 cells, a 60% decrease of Dipa mRNA levels was observed (Figure 3M), and Dipa down-regulation caused a modest increase in adipogenesis (Figure 3N and O). These data confirm the role of DIPA as a negative regulator of adipogenesis [16], but importantly they identify TRIO, GPS2 and HMMR as new proteins that also negatively regulate the adipogenic process in 3T3-L1 cells.

GPS2 and DIPA localization in transfected 3T3-L1 cells

Both GPS2 and DIPA have been previously found to localize to the nucleus [16,20]. To investigate the effect of ANKRD26 on the localization of both GPS2 and DIPA proteins, confocal immunofluorescence studies were performed in 3T3-L1 cells individually over-expressing GPS2-Myc or DIPA-Myc proteins, or simultaneously over-expressing Flag-ANKRD26-C with GPS2-Myc or DIPA-Myc proteins. As shown in Figure 4Ai and Bi, both GPS2-myc and DIPA-myc proteins are localized in the nuclei of cells transfected with pcDNA3.1-GPS2-Myc and pcDNA3.1-DIPA-Myc, respectively. When co-transfected with Flag-ANKRD26-C, which is mainly located in the cytosol (Figure 4Av and viii), GPS2-Myc mostly co-localized with Flag-ANKRD26-C in the cytoplasm of 3T3-L1 cells (Figure 4Av–vi). Similarly, when the DIPA-Myc protein was expressed together with Flag-ANKRD26-C the location of DIPA was predominantly in the cytoplasm (Figure 4Bi–vi). These data confirm our finding that GPS2 and DIPA interact with ANKRD26 and provide a possible mechanism by which ANKRD26 can regulate the activity of these two proteins by removing them from the nucleus in 3T3-L1 cells.

We previously reported that full-length ANKRD26 is mainly located close to the plasma membrane, although some can be detected in the cytoplasm. To investigate if the full-length protein could decrease the amount of DIPA or GPS2 in the nucleus, cells were transfected with GPS2-myc or DIPA-myc and full-length ANKRD26. Unfortunately, very few transfected cells were found to express ANKRD26 and we could not get an answer to this question.

Expression of Ankrd26, Trio, Gps2, HMMR and Dipa during adipogenic induction in 3T3-L1 cells

To determine if the expression of endogenous Ankrd26 and its interacting partners were altered during adipogenesis in 3T3-L1 cells, we performed Real Time quantitative PCR using RNA isolated from 3T3-L1 treated with an adipogenic cocktail at various time points as described in the Methods. As shown in Figure 5, Ankrd26 expression increased 2-fold in the post-confluent cells as compared to pre-confluent condition and remains unchanged during adipogenic induction. Trio expression increased almost 3-fold in post-confluent condition and its levels remained high up to day 8. The expression of Dipa was increased almost 4-fold at day 2 of induction and remained high until day 4 but decreased on day 8 of adipogenic induction. These results indicate that the expression of Ankrd26, as well as the expression of its interacting partners is differentially regulated during adipogenesis.

Discussion

In the present work, we identified 13 potential interacting partners for ANKRD26 by yeast two-hybrid screening, and validated as novel ANKRD26 interacting proteins TRIO, GPS2, DIPA, and HMMR by co-immunoprecipitation assays in mammalian cells. Furthermore, our analysis of adipogenesis showed that the selective down-regulation of Ankrd26, Trio, Gps2, Hmmr and Dipa increased adipocyte differentiation upon induction in 3T3-L1 cells. These finding indicated that ANKRD26, TRIO, GPS2, HMMR and DIPA are regulators of adipogenesis. Further, GPS2 and DIPA proteins, that usually are located in the nucleus, become translocated into the cytoplasm when co-transfected with the C-terminus of ANKRD26 in 3T3-L1 cells, suggesting that the C-terminus may modulate the localization and function of these two proteins. However, due to our inability to transfect the very large full-length Ankrd26 cDNA into cells, we do not know if the full-length protein will have a similar interaction with the interacting proteins or change the nuclear localization of DIPA and GPS2. In addition we do not know if the interaction of one of the interacting partners affects the interaction of other interacting proteins with the carboxy-terminus of Ankrd26. Studies are underway to determine the binding site for each of the interacting proteins on Ankrd26.

The ANKRD26 gene was originally identified as the ancestor of primate specific ANKRD30A and the POTE gene family [21]. It maps to chromosome 10p12.1 and encodes a protein of 192 kDa, which is located close to the inner aspect of the plasma membrane [6]. The ANKRD26 protein contains two conserved domains: Ankyrin repeats, located from amino acids 74–199, and helical regions (743–1538), which are structurally similar to the α-spectrin family proteins [6]. The presence of these two domains, known to mediate protein-protein interactions [22,23], suggested that ANKRD26 might play a role as an adaptor protein [6]. From the two-hybrid screening data only one protein (ANKRD17) was found to interact with the ankyrin repeat region at the N-terminus of ANKRD26; all the other 12 proteins interacted with region 901–1702 of ANKRD26 that contains the spectrin-like coiled-coil domains. These findings indicate that the coiled-coil domain at the C-terminus of ANKRD26 rather than Ankyrin domain is mainly involved in ANKRD26 protein-protein interactions, and is likely to be responsible for its biological functions. In support of this last statement are our previous data obtained in mutant mice [6,7], in which removal of the region encoding amino acids 1212–1710, encompassing part of the spectrin-like helices and all the C-terminus of Ankrd26, cause extreme hyperphagia and severe obesity [6]. Furthermore, Ankrd26 mutant mice develop an unusual form of obesity-induced diabetes in which white adipose
tissue preserves its sensitivity to insulin in the context of whole body insulin resistance, and shows an improved sensitivity to the hormone when the mutant mice were pair fed with normal mice [7]. These data indicate that the C-terminus of Ankrd26 has at least two functions: one is to control the response to insulin in white adipose tissue; the other is to control appetite and satiety.

Recently we demonstrated that partial disruption of the Ankrd26 gene regulates adipocyte differentiation both at the level of progenitor commitment and at early and late differentiation steps in MEF cells from Ankrd26 mutant mice and that this process is associated with ERK-1/2 activation [8]. Here we show that down-regulation of Ankrd26 expression caused an increase in adipogenesis when 3T3-L1 cells were transfected with a specific shRNA for the murine endogenous Ankrd26. All together these findings indicate that Ankrd26 has an important role in regulating differentiation of adipocytes.

The protein TRIO was initially identified as a binding partner for LAR, a trans-membrane protein tyrosine phosphatase. Its association with LAR was suggested to play a key role in the integration of diverse signals needed for cell-matrix interaction and cytoskeletal rearrangements during cell migration [9–11]. TRIO is a multidomain protein, which contains two guanine nucleotide exchange factor domains that promote Rho and Rac1 activation, and a serine/threonine kinase domain [9]. Furthermore, TRIO also possesses two pleckstrin homology domains that can recruit TRIO to different membranes, and four spectrin-like domains and an Ig-like domain that can mediate protein-protein interactions [9]. Here, we identified TRIO as a novel ANKRD26 interacting protein and we demonstrated for the first time the involvement of

Figure 4. Nuclear localization of GPS2 and DIPA is affected in 3T3-L1 cells over-expressing Flag-ANKRD26-C. A) 3T3-L1 cells transfected with GPS2-Myc (i–ix) and Flag-ANKRD26-C vectors (iv–ix) were double stained with antibodies against anti-Myc (i, iv, vii) and anti-Flag (ii, v, viii) and with DAPI solution for the nucleus staining (iii, vi, ix). B) 3T3-L1 cells transfected with DIPA-myc (i–ix) and Flag-ANKRD26-C vectors (iv–ix) were stained as in B. The images labeled iii, vi and ix are the merged fluorescent images. Note that only co-transfected cells in Panels vii, viii and ix demonstrate cytosolic localization on GPS2 and DIPA.

doi:10.1371/journal.pone.0038130.g004
TRIO as negative regulator of adipogenesis in 3T3-L1 cells. Although the mechanism by which TRIO can inhibit adipogenesis, and how ANKRD26 can interfere with the function of TRIO are not yet known and are under investigation. We suggest that TRIO could regulate adipogenesis in combination with LAR and/or through the activation of Rho GTPase signaling. In support of this hypothesis are the recent reports that LAR and Rho signaling are negative regulators of adipogenesis [24,25]. Kim et al. reported in human mesenchymal stem cells and in 3T3-L1 cells that the knock-down of endogenous LAR induced a dramatic increase of adipogenesis in these cells, while its over-expression caused a strong reduction of adipogenic differentiation by inhibition of insulin/insulin receptor signaling [24]. On the other hand, Sordella et al. reported that the modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis [25]. Indeed, mice lacking the Rho inhibitory protein p190-B RhoGAP exhibit a complete absence of mature adipocytes and MEF cells derived from these mice are defective in adipogenesis and this defect is rescued by inhibiting Rho kinase. Furthermore, the introduction of excessive Rho activity in MEF cells from control mice and in 3T3-L1 cells is sufficient to disrupt adipogenesis [25].

We have also shown that the selective down-regulation of the expression of three other ANKRD26 interacting partners, GPS2, HMMR and DIPA, enhances the proportion of differentiated cells. GPS2 was originally identified based on its ability to suppress lethal G protein subunit-activating mutations in the yeast pheromone responsive pathway [12], and its over-expression in mammalian cells potentially suppresses a RAS- and MAPK-mediated signal and interferes with JNK activity [12,13]. Most importantly, GPS2 was found as an integral subunit of N-CoR-HDAC3 complex. It interacts directly with N-CoR and transducing beta-like protein 1 (TβL1) proteins inside the complex and it is essential for its assembly and stabilization [14]. It was recently demonstrated that the adipogenic transcription factor proliferator-activated receptor gamma (PPARγ) recruits N-CoR in the absence of its ligand, and that this co-repressor down-regulates PPARγ transcriptional activity. Furthermore, the silencing of N-CoR increases the expression of adipocyte specific genes and of adipogenesis in 3T3-L1 cells [26]. Similarly, PPARγ recruits HDAC3 to maintain transcriptional repression of its target genes [27]. Our findings demonstrate for the first time that GPS2 can act as a repressor of adipogenesis in 3T3-L1 cells and that its sequestration from the nucleus mediated by ANKRD26 may inhibit its function. Whether this regulatory process is mediated by GPS2 alone or in combination with the other proteins of the N-CoR-HDAC3 complex remain to be clarified.

The protein DIPA was initially identified as an interacting protein for the viral HDAg and it was shown to affect hepatitis D virus replication in vitro [15]. Bezy et al. recently described DIPA also as a novel interacting partner for the adipocyte transcription factors C/EBPβ and δ. They showed that over-expression of DIPA affects adipogenesis in 3T3-L1 cells; while its silencing enhances this process as we also showed in our study. Furthermore, they demonstrated that DIPA can co-localize with these two
proteins in the nucleus of 3T3-L1 cells and may negatively modulate their transcriptional activity inhibiting adipogenesis [16]. Thus, our findings confirm the role of DIPA as negative regulator of this process and support the possible role of ANKRD26 as counter-regulator of DIPA mechanism by regulating DIPA localization.

HMMR is an oncogenic protein implicated in the progression of many human cancers, such as breast, gastric, and prostate cancers [29]. It was originally identified as a soluble protein, which binds to CD44 or hyaluronan and promotes cell motility and invasion through sustained stimulation of the activity of ERK1/2 kinase [18,28–30]. Within the cell, HMMR plays a role in the regulation of mitosis through its association with microtubules [17], and it regulates the normal development of breast epithelial cells forming a complex with BRCA1 [31]. Furthermore it was recently shown that intracellular HMMR, performs scaffolding functions to control both activity and targeting of ERK1/2 to tubulin [32]. Here, we identified HMMR as a novel ANKRD26 interacting partner and showed for the first time its involvement as regulator of adipogenesis. Although how HMMR inhibits adipocyte differentiation and how ANKRD26 interferes with HMMR function remain to be clarified, we suggest that it could involve HMMR’s ability to modulate ERK1/2 activation. It should be noted that the adipogenic induction in 3T3L1 is consistently higher during selective knock down of each of the interacting partners of Ankrd26 yet the endogenous expression of those proteins are not consistently lower during the adipogenic induction suggesting the involvement of multiple pathways and complex interaction of these interacting proteins in vivo.

In summary, we have identified several novel proteins that participate in the regulation of adipogenesis and we have shown that the region at the C-terminus of ANKRD26 that contains spectrin-like helices is responsible for its interaction with these proteins and in its regulation of adipogenesis. The identity of the residues that are responsible for the specific binding between ANKRD26 and its newly identified partners and the mechanism by which these proteins regulate adipogenesis are under investigation.

Materials and Methods

Yeast two-hybrid analysis

Yeast two-hybrid screening and analysis was performed by Myriad Genetics. Briefly, a bait construct expressing various fragments of ANKRD26 protein was fused to the C-terminus of a Gal4 DNA binding domain (residues 1–147). Each bait was transformed into the yeast strain PNY200. Prey constructs, expressing cDNA from human brain, testis or mouse embryo mRNA fused to the C-terminus of a Gal4 activation domain (amino acids (aa) 768–881), were transformed into yeast strain BK100. PNY200 cells (bait) were mated with BK100 cells (prey), and the desired diploid cells with positive interaction were selected on 3′-amino-1,2,4-triazole (3AT). After mating, the diploid cells were plated onto media lacking leucine and lysine and grown for 3 days on 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal) to identify positive interactions. Prey constructs were validated on a second set of diploids and identified clones were sequenced.

293/T cells: culture conditions and transient transfection

293/T cells (ATCC) were maintained in DMEM media (Quality Biologicals) supplemented with 10% FBS (Quality Biologicals), 2 mM L-Glutamine, 1 mM sodium pyruvate and 1% penicillin-streptomycin solutions in a humidified 5% CO2 incubator at 37°C. For transient transfection, expression vectors for pcDNA3.1-Flag-ANKRD26-C (aa 1212–1710), pcDNA3.1-DIPA-Myc, pcDNA3.1-GPS2-Myc, pcDNA3.1-Trio-Myc and pcDNA3.1-HMMR-Myc were transfected individually or in combination into 293/T cells using lipofectamine reagent (Invitrogen) following the manufacturer’s protocol. Cells were lysed 48 hr after transfection (see below).

Cell lysate preparation, IP and western blot (WB) analysis

Both 293/T and 3T3-L1 (ATCC) cells were harvested and washed in PBS, and then lysed in Lysis Buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% NP40, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 10 μM PMSF. Samples were incubated on ice 30 min after the addition of Lysis Buffer and then cell lysates were clarified by centrifugation at 15,000 g for 10 min at 4°C. The protein concentration of the cell lysates was determined using the Coomassie blue protein assay (Bio-Rad Laboratories). Protein lysates were then analyzed by SDS-PAGE, transferred to a PVDF membrane and subjected to WB analysis. For each IP experiment about 1 μg of protein lysate from 293/T cells transfected with the various combinations of vectors was incubated with 1.5 μg of anti-myc antibody (Sigma Aldrich) for 2 hr at 4°C. After incubation, 40 μl of protein A sepharose (Invitrogen) in a 1:1 mixture of protein A sepharose and Lysis Buffer were added to the IP samples. Purified interacting complex was released from protein A sepharose beads by boiling in SDS-PAGE sample buffer and resolved on a 4–20% Tris-glycine gel. Samples were then subjected to WB analysis. Membranes were firstly probed with antibodies to Myc (Sigma Aldrich), Flag M2 (Sigma Aldrich), PPARγ (Santa Cruz Inc), C/EBPζ (Cell Signaling), and β-tubulin (Sigma Aldrich) and then with secondary mouse or rabbit antibodies (GE Healthcare) before detection of the signal with ECL plus (GE Healthcare).

Oil-red-o staining

Lipid droplets in differentiating or mature adipocytes were stained with the oil-red-O method as described [8]. Oil-red-O stained cells were scanned to obtain macroscopic pictures of cells. Cells were finally eluted with absolute isopropanol and the extracted red dye was measured with spectrophotometer at 490 nm.

ShRNA and siRNA transduction

1.105 3T3-L1 cells were transduced with specific shRNA lentivirus particles for Ankrd26 (TRCN0000254144), Trio (TRCN0000254107), Gps2 (TRCN000037101), Dipa (TRCN0000248678), HMMR (TRCN000071589) and for the control shRNA SHC002V. All shRNA were purchased from Sigma Aldrich. After 3 days cells were selected with puromycin for 10 days. The puromycin-resistant cells were then collected, maintained in selection media and adipogenesis was induced as previously described.

Immunofluorescence

3T3-L1 cells transfected with pcDNA3.1-Flag-ANKRD26-C, pcDNA3.1-DIPA-Myc and pcDNA3.1-GPS2-Myc expression vectors were fixed in 4% formalin solution, subjected to membrane permeabilization with PBS containing 0.1% TritonX-100, and then blocked for 1 hr in PBS containing 5% FBS and 3% BSA. Cells were then incubated with rabbit anti-myc and/or mouse anti-Flag antibodies for 2 hr at RT. After washing, cells were then incubated for 1 h with secondary antibody-fluorochrome-labeled (Alexa Fluor 594 anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit IgG; Invitrogen). Cells were then washed and incubated in a DAPI solution for 10 min to stain the nucleus. Finally, slides were mounted with cover slip and observed on the Zeiss 510 confocal microscope (Carl Zeiss).
Real time quantitative PCR

Total RNA extraction, cDNA synthesis and Real Time quantitative PCR were performed as described [8]. Quantitative PCR analysis of cells in the presence of corresponding shRNA was performed using mRNA isolated from cells before adding the adipogenic cocktail for differentiation. Primer sequences are listed in Table 2.

| Primer Name | Orientation | Primer Sequences | Primer Efficiency |
|-------------|-------------|------------------|-------------------|
| Ankrd26     | Forward     | 5'-ggcagcctcatactttaaa-3' | 91 |
|             | Reverse     | 5'-ggcagcctcatactttaaa-3' | 91 |
| Trio        | Forward     | 5'-ggttcgctcaggtgaagggg-3' | 95 |
|             | Reverse     | 5'-ggttcgctcaggtgaagggg-3' | 95 |
| Gps2        | Forward     | 5'-gttgggttgtggcctgttagat-3' | 86 |
|             | Reverse     | 5'-gttgggttgtggcctgttagat-3' | 86 |
| Dipe        | Forward     | 5'-gttgttgtgtgtgtgtgtagat-3' | 86 |
|             | Reverse     | 5'-gttgttgtgtgtgtgtgtagat-3' | 86 |
| HmrR        | Forward     | 5'-gagagagagagagagagagag-3' | 91 |
|             | Reverse     | 5'-gagagagagagagagagagag-3' | 91 |
| Actin       | Forward     | 5'-actgtggtgtcagcttagtg-3' | 91 |
|             | Reverse     | 5'-actgtggtgtcagcttagtg-3' | 91 |

Table 2. Real Time Quantitative PCR primer sequences and primer efficiencies.

References

1. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782–787.
2. Walder K, Segal D, Jowett J, Blangero J, Collier GR (2003) Obesity and diabetes gene discovery approaches. Curr Pharm Des 9: 1357–1372.
3. Haulam DW, James WP (2005) Obesity. Lancet 366: 1197–1209.
4. Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8: 657–662.
5. Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, et al. (2003) RHAMM is a centromernal protein that interacts with dynein and maintains spindle pole stability. Mol Cell Biol 14: 2262–2226.
6. Djinovic-Carugo K, Gautel M, Yla ¨nne J, Young P (2002) The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett 513: 119–123.
7. Lanier LM, Gertler FB (2000) From Abl to actin: Abl tyrosine kinase and protein- and mitogen-activated protein kinase-mediated signal transduction in mammalian cells, 3.761–3768.
8. Ben-A Y, Bera TK, Liu X, Pastan I (2011) Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem 286: 5466–5471.
9. Rasic GA, Bera TK, Liu X, Pastan I (2011) Ankrd26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem 286: 5466–5471.
10. Derant A, Serra-Pages C, Seipel K, O’Brien S, Tang M, et al. (1996) The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. Proc Natl Acad Sci USA 93: 5466–5471.
11. Lanier LM, Gertler FB (2000) From Abl to actin: Abl tyrosine kinase and associated proteins in growth cone motility. Curr Opin Neurobiol 10: 80–87.
12. Medley GJ, Buchbinder EG, Tachibana K, Ngo H, Serra-Pages C, et al. (2003) Signaling between focal adhesion kinase and trio. J Biol Chem 278: 13263–13270.
13. Spahn BH, Bowldin KS, Pasol AR, Staub SF, Koo D, et al. (1996) Two human cDNAs, including a homolog of Arabidopsis Fus3 (COP1), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells. Mol Cell Biol 16: 6690–6706.
14. Jia D, Tanamoto H, Giam CZ, Chun RF, Guntik JD, et al. (1997) A human suppressor of c-jun N-terminal kinase 1 activation by tumor necrosis factor alpha. J Biol Chem 272: 25016–25023.
15. Zhang J, Kalkum M, Charr BT, Roeder RG (2002) The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit Gp2. Mol Cell 9: 611–623.
16. Brazas R, Gannem D (1996) A cellular homolog of hepatitis delta antigen: implications for viral replication and evolution. Science 274: 90–94.
17. Bezy O, Elabed C, Cochet O, Petersen RK, Krishnan K, et al. (2005) Delta-interacting protein A, a new inhibitory partner of CCAAT-enhancer-binding protein beta, implicated in adipocyte differentiation. J Biol Chem 280: 11432–11438.
18. Maxwell CA, Keats JJ, Grunow M, Sun X, Yen T, et al. (2003) RHAMM is a centromeral protein that interacts with dynein and maintains spindle pole stability. Mol Cell Biol 14: 2262–2226.
19. Turley EA, Austen L, Vandeligt K, Clary C (1991) Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of rasmiformed cells. J Cell Biol 112: 1041–1047.
20. Jefcoat CR, Wang S, Liu X (2008) Methods that resolve different contributions of clonal expansion to adipogenesis in 3T3-L1 and C3H10T1/2 cells. Methods Mol Biol 456: 173–193.
21. Sanjil S, Biesner A, Hronzini A, Nilsson LM, Lundstrom T, et al. (2007) Involvement of corepressor complex subunit Gp2 in transcriptional pathways governing human bile acid biosynthesis. Proc Natl Acad Sci USA 104: 15663–15670.
22. Hahn B, Bera TK, Pastan I, Lee B (2006) Duplication and extensive remodeling shaped POTE family genes encoding proteins containing ankyrin repeat and coiled coil domains. Gene 366: 238–245.
23. Djinovic-Carugo K, Gantut M, Yamanne J, Young P (2002) The spectrin repeat: a structural platform for cytoskeletal protein assemblies. FEBS Lett 513: 119–123.
24. Li J, Mahajan A, Tsai MD (2006) Ankyrin repeat: a unique motif mediating protein-protein interactions. Biochemistry 45: 15168–15178.
25. Kim WK, Jung H, Kim DH, Kim YE, Chung JW, et al. (2009) Regulation of adipogenic differentiation by LAR tyrosine phosphatase in human mesenchymal stem cells and 3T3-L1 preadipocytes. J Cell Sci 122: 4160–4167.
26. Sordella R, Jiang W, Chen GC, Caruso M, Settleman J (2003) Mutation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell 113: 147–156.
27. Yu C, Markan K, Temple KA, Deplewski D, Brady MJ, et al. (2005) The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell 3: 903–910.

Statistical analysis

Data are expressed as means ± SEM and statistical significance between groups was analyzed by 2-tailed Student’s t test. P values of <0.05 were considered statistically significant.

Author Contributions

Conceived and designed the experiments: XFL TKB IP. Performed the experiments: XFL TKP CR TE ZF. Analyzed the data: XFL TKB GAR IP. Contributed reagents/materials/analysis tools: XFL TKB. Wrote the paper: XFL TKB GAR IP.
28. Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121: 925–932.

29. Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, et al. (2006) McCarthy JB, Bisell MJ, Turley EA. Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 175: 1017–1028.

30. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, et al. (2007) The hyaluronan receptors CD44 and rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282: 16667–16680.

31. Maxwell CA, Benitez J, Gomez-Baldó L, Osorio A, Bonifaci N, et al. (2011) Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 9: e1001199.

32. Tolg C, Hamilton SR, Morningstar L, Zhang J, Zhang S, et al. (2010) RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 285: 26461–26474.